SRPT
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E 7.17, P/S 1.03
- Low P/S ratio
- Low Forward P/E
- Negative earnings make P/E irrelevant
- Graham Number unavailable due to lack of positive earnings
Ref Growth rates
- Revenue growth -32.70%
- EPS growth -306.8%
- Negative operating margins
Ref Historical trends
- Recent 1-month bounce (+25.6%)
- 1Y Change -59.9%
- 3Y Change -82.8%
- 5Y Change -69.3%
Ref Piotroski F-Score
- Current Ratio 2.32
- Piotroski F-Score 1/9
- ROE -53.47%
- Operating Margin -92.58%
Ref Yield, Payout
- No dividend paid
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SRPT and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SRPT
Sarepta Therapeutics, Inc.
Primary
|
-69.3% | -82.8% | -59.9% | -4.3% | +25.6% | +1.8% |
|
DAWN
Day One Biopharmaceuticals, Inc.
Peer
|
-8.7% | +69.0% | +205.7% | +189.6% | +0.6% | +0.1% |
|
HTFL
Heartflow, Inc.
Peer
|
-10.1% | -10.1% | -10.1% | -19.5% | +21.3% | +8.5% |
|
ATEC
Alphatec Holdings, Inc.
Peer
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
|
STOK
Stoke Therapeutics, Inc.
Peer
|
+22.0% | +332.9% | +384.7% | +11.2% | +20.1% | +8.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SRPT
Sarepta Therapeutics, Inc.
|
BEARISH | $2.26B | - | -53.5% | -32.5% | $21.55 | |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
NEUTRAL | $2.22B | - | -22.7% | -67.8% | $21.46 | Compare |
|
HTFL
Heartflow, Inc.
|
BEARISH | $2.31B | - | -111.4% | -66.3% | $26.95 | Compare |
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | Compare |
|
STOK
Stoke Therapeutics, Inc.
|
BEARISH | $2.2B | - | -2.4% | -3.7% | $37.27 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | MAYO STEPHEN L. | Director | Sale | 7,239 | $123,208 |
| 2026-02-27 | RODINO-KLAPAC LOUISE | Officer | Stock Award | 8,125 | - |
| 2026-02-27 | ESTEPAN IAN MICHAEL | Chief Operating Officer | Stock Award | 8,125 | - |
| 2026-02-26 | ESTEPAN IAN MICHAEL | Chief Operating Officer | Option Exercise | 7,450 | $102,140 |
| 2026-01-29 | NICAISE CLAUDE M.D. | Director | Option Exercise | 10,500 | $143,955 |
| 2026-01-27 | BEHRENS M KATHLEEN | Director | Option Exercise | 10,500 | $143,955 |
| 2025-12-16 | ESTEPAN IAN MICHAEL | Chief Operating Officer | Sale | 13,187 | $294,202 |
| 2025-12-05 | INGRAM DOUGLAS S | Chief Executive Officer | Stock Award | 539,084 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Sarepta Therapeutics is leveraging manufacturing partnerships to support its PMO and gene therapy pipelines, including the SRP-9003 LGMD program. The company faces significant regulatory risks, including an FDA clinical hold on LGMD trials, the revocation of its AAVrh74 platform designation, and potential adverse outcomes from the ESSENCE confirmatory trial for VYONDYS and AMONDYS. Additional headwinds include the impacts of the ELEVIDYS suspension and broader government healthcare cost-containment and pricing reforms.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning SRPT from our newsroom.